Toronto, Canada, March 1, 2022 – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB: DTMXF) (the "Company" or "Datametrex") today announced the launch of a beta version of its Medi-Call telehealth app.
Medi-Call, a Canada-based subscription service that proactively connects patients with doctors, will begin beta testing the app today with a focused group of physicians and end-users in Ontario and Quebec. This testing will allow the Company to make any necessary changes and ensure the best user experience for physicians and clients. The beta version will also help prepare Datametrex for a full and seamless launch of the app as quickly as possible while gathering important quality assurance feedback from valued testers.
“To get the app ready for beta testing in this short period is a milestone for the Company and shows our commitment and belief in the potential of the sector,’’ said Marshall Gunter, CEO of Datametrex AI. “With this new application, we are looking forward to meeting the growing demand from physicians and potential patients by taking the next step to capture the full potential of Medi-Call’s services.”
The Medi-Call app will help physicians effectively manage their appointments, while simultaneously providing faster treatment and care for patients. The launch comes at a time when digital access to healthcare is more important than ever, and current data shows more people are turning to telehealth for their basic healthcare and mental health needs, a trend amplified by the pandemic.
According to recent findings by the American Psychiatric Association (APA), 82% of Americans have used telehealth services to meet with a medical professional during the pandemic. More interestingly, 69% of respondents said they had used telehealth through a video format. Only 38% had met with a doctor over the phone.
Even more positive, a survey by the Canadian Medical Association found that about 91% of Canadians were satisfied with their teleconsultation experience
Health technology and telehealth in Canada took a big leap in 2020 and are expanding worldwide. By 2027, the telehealth market could be worth over $830 billion.
Source: The Motley Fool
Medi-Call is an integrated grid system that connects patients with providers in real-time:
Solves accessibility issues for patients living in rural or isolated communities or with limited mobility
Improves coordination and communication of treatment among healthcare team members and their patients
Facilitates mobile health care services including prescriptions
Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). The Datametrex mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain.
For additional information on Datametrex and other corporate information, please visit the Company's website at www.datametrex.com.
For further information, please contact:
Communications & Investor Relations
Kristina Colpitts email@example.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. In particular, there is no guarantee that the parties will successfully negotiate and enter into a definitive agreement on mutually acceptable terms or complete the Transaction in the manner contemplated herein, if at all, that the due diligence of any of the parties will be satisfactory, or that the parties will obtain any required board, shareholder, third-party and/or regulatory or other governmental approvals, if any. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not undertake to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.